Compare AbbVie Inc (ABBV) vs ConocoPhillips (COP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ConocoPhillips — how do they compare? AbbVie Inc trades at $254.26 (market cap $449.91B), while ConocoPhillips trades at $109.94 (market cap $132.11B). The key difference: AbbVie Inc is far larger — about 3.4× ConocoPhillips's market cap, and ConocoPhillips pays the higher dividend (3.1%). Which is the better fit depends on your goals.
| ABBV | COP | |
|---|---|---|
Market Cap | $449.91B | $132.11B |
Sector | Health | Energy |
52-Week High | $261.07 | $133.80 |
52-Week Low | $184.85 | $85.66 |
Enterprise Value | $513.38B | $149.08B |
Dividend Yield | 2.72% | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
ConocoPhillips (COP) trades at $108.44, up 3.54% today, with strong analyst support (74.5% buy ratings) and a $148.86 consensus price target suggesting significant upside. The company maintains solid fundamentals with a 12.58% net margin and 11.25% ROE, though revenue has declined from $78.5B in 2022 to $58.9B in 2025. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $102-103 levels.
COP presents a compelling value opportunity with attractive valuation multiples (P/E 17.56, EV/EBITDA 5.81) and consistent cash flow generation. However, investors face risks from volatile oil prices, declining revenue trends, and geopolitical uncertainties affecting energy markets. The upcoming Q2 earnings report on August 6 will be critical for confirming the bullish analyst outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
